个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yang Yu[1] ; Sun Juxian[2] ; Wu Mengchao[2] ; Lau Wan Yee[2,3] ; Zheng Shusen[4] ; Wang Xue-Hao[5] ; Chen Xiaoping[6] ; Fan Jia[7] ; Dong Jiahong[8] ; Cai Jianqiang[9] ; Chen Minshan[10] ; Chen Yongjun[11] ; Cheng Zhangjun[12] ; Dai Chaoliu[13] ; Shan Jianzhen[14] ; Du Cheng-You[15] ; Fang Chihua[16] ; Hu Heping[17] ; Ji Zhili[18] ; Jia Weidong[19] ; Li Gong[20] ; Li Jing[21] ; Li Jiangtao[22] ; Liu Chang[23] ; Liu Fubao[24] ; Ma Yong[25] ; Mao Yilei[26] ; Niu Zuoxing[27] ; Shen Jie[28] ; Shi Jie[2] ; Shi Xuetao[29] ; Song Wenjie[30] ; Sun Hui-Chuan[7] ; Tan Guang[31] ; Tao Ran[32] ; Wang Xiaohu[33] ; Wen Tianfu[34] ; Wu Liqun[35] ; Xia Jinglin[36] ; Xiang Bang-De[37] ; Yan Maolin[38] ; Ying Mingang[39] ; Zhang Ling[40] ; Zhang Xuewen[41] ; Zeng Zhao Chong[42] ; Zhang Yubao[43] ; Zhang Zhiwei[44] ; Zhou Jie[45] ; Zhou Cuncai[46] ; Zhou Jun[47] ; Zhou Ledu[48] ; Zhou Xinmin[49] ; Zhu Ji[50] ; Zhu Zhenyu[51] ; Zhang Qi[52] ; Li Qiu[1] ; Cheng Shuqun[2] ; on behalf of Chinese Association of Liver Cancer and Chinese Medical Doctor Association[1] ;
机构： [1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [2]Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. [3]Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. [4]Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, China. [5]Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. [6]Hepatic Surgery Center, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. [7]Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, China. [8]Department of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China. [9]Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. [10]Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. [11]Department of Hepatobiliary Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [12]Department of Hepatobiliary Surgery, Zhongda Hospital, Southeast University, Nanjing, China. [13]Department of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China. [14]Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. [15]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. [16]Department of Hepatobiliary Surgery, Zhujiang Hospital, First Military Medical University, Guangzhou, China. [17]Department of Gastroenterology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. [18]Department of General Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. [19]Department of General Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China. [20]Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China. [21]Department of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China. [22]Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. [23]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [24]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China. [25]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China. [26]Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China. [27]Department of Gastroenterology, Shandong Cancer Hospital, Jinan, China. [28]Department of Medical Oncology, Cancer Center, Nanjing Drum Tower Hospital, Medical College of Nanjing University, Nanjing, China. [29]Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, China. [30]Department of Hepatobiliary Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China. [31]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China. [32]Department of Hepatobiliary Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China. [33]Department of Radiation Oncology, Gansu Cancer Hospital, Lanzhou, China. [34]Department of Liver Surgery, Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu, China. [35]Division of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China. [36]Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. [37]Department of Hepatobiliary Surgery, Cancer Hospital Affiliated to Guangxi Medical University, Nanning, China. [38]Department of Hepatobiliary and Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China. [39]Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, China. [40]Department of Hepatobiliary Surgery, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China. [41]Department of Hepatobiliary and Pancreas Surgery, The Second Hospital of Jilin University, Changchun, China. [42]Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. [43]Department of Hepatobiliary Surgery, Cancer Hospital Affiliated to Harbin Medical University, Harbin, China. [44]Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [45]Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China. [46]Department of Hepatobiliary Surgery, Jiangxi Provincial Cancer Hospital, Jiangxi, China. [47]Department of Medical Oncology, Beijing Cancer Hospital, Beijing, China. [48]Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China. [49]Department of Gastroenterology, Xijing Hospital, Air Force Medical University, Xi'an, China. [50]Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China. [51]Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Beijing, China. [52]Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
出处：
DOI： 10.1159/000526038
ISSN：

摘要：
Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment.In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the "Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)" based on current clinical studies and clinical medication experience for reference in China.The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 2 区 胃肠肝病学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 胃肠肝病学 1 区 肿瘤学
JCR分区：
出版当年[2022]版：
Q1 GASTROENTEROLOGY & HEPATOLOGY Q1 ONCOLOGY
最新[2023]版：
Q1 GASTROENTEROLOGY & HEPATOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Yang Yu,Sun Juxian,Wu Mengchao,et al.Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)[J].LIVER CANCER.2022,11(6):511-526.doi:10.1159/000526038.
APA：
Yang Yu,Sun Juxian,Wu Mengchao,Lau Wan Yee,Zheng Shusen...&on behalf of Chinese Association of Liver Cancer and Chinese Medical Doctor Association.(2022).Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).LIVER CANCER,11,(6)
MLA：
Yang Yu,et al."Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)".LIVER CANCER 11..6(2022):511-526

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号